Literature DB >> 12574843

Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study.

K Geboes1, M Y El-Zine, I Dalle, S El-Haddad, P Rutgeerts, P Van Eyken.   

Abstract

Tenascin is an extracellular matrix protein involved in morphogenesis of muscle tissue and in wound healing. In the present study we examined its distribution in tissue from patients with inflammatory bowel disease. Intestinal biopsies from 10 normal controls, 15 patients with Crohn's disease, and 6 with ulcerative colitis were studied. Samples were obtained both from uninvolved and involved areas. Mucosal tenascin is increased in ulcerative colitis and Crohn's disease, especially in areas of ulceration. In Crohn's disease, tenascin is also strongly expressed in the submucosa and in smooth muscle cells of the muscularis mucosae and propria, especially in areas of stricture. We conclude that tenascin is involved in stricture formation in Crohn's disease and that it is a marker of phenotypic change in smooth muscle cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12574843     DOI: 10.1177/106689690100900404

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  12 in total

1.  Results of the Fifth Scientific Workshop of the ECCO (II): Pathophysiology of Perianal Fistulizing Disease.

Authors:  Britta Siegmund; Roger M Feakins; Giorgos Barmias; Juliano Coelho Ludvig; Fabio Vieira Teixeira; Gerhard Rogler; Michael Scharl
Journal:  J Crohns Colitis       Date:  2015-12-17       Impact factor: 9.071

Review 2.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases.

Authors:  Florian Rieder; Claudio Fiocchi; Gerhard Rogler
Journal:  Gastroenterology       Date:  2016-10-05       Impact factor: 22.682

Review 3.  Reversibility of Stricturing Crohn's Disease-Fact or Fiction?

Authors:  Dominik Bettenworth; Florian Rieder
Journal:  Inflamm Bowel Dis       Date:  2016-01       Impact factor: 5.325

4.  Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs - a systematic review.

Authors:  Dominik Bettenworth; Florian Rieder
Journal:  Fibrogenesis Tissue Repair       Date:  2014-03-29

5.  The correlation between tenascin-C expression, and formation of intestinal stricture.

Authors:  Emrullah Erdem; Koray Kochan; Nurcan Paker; Yasemin Gokden; Ayca Salturk Degirmenci; Fatin Kocak; Can Gonen
Journal:  North Clin Istanb       Date:  2015-01-24

6.  Topographic, histological and molecular study of aberrant crypt foci identified in human colon in different clinical groups.

Authors:  Shouriyo Ghosh; Brijnandan Gupta; Pavan Verma; Sreenivas Vishnubathla; Sujoy Pal; Nihar R Dash; Siddhartha Datta Gupta; Prasenjit Das
Journal:  Intest Res       Date:  2018-01-18

Review 7.  Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide.

Authors:  Motomichi Fujita; Manabu Sasada; Takuya Iyoda; Fumio Fukai
Journal:  Molecules       Date:  2020-07-16       Impact factor: 4.411

8.  Peptide TNIIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via β1-Integrin Activation in Fibroblasts.

Authors:  Motomichi Fujita; Yuka Ito-Fujita; Takuya Iyoda; Manabu Sasada; Yuko Okada; Kazuma Ishibashi; Takuro Osawa; Hiroaki Kodama; Fumio Fukai; Hideo Suzuki
Journal:  Int J Mol Sci       Date:  2019-06-05       Impact factor: 5.923

9.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

10.  Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease.

Authors:  Christine Breynaert; Tom Dresselaers; Clémentine Perrier; Ingrid Arijs; Jonathan Cremer; Leentje Van Lommel; Kristel Van Steen; Marc Ferrante; Frans Schuit; Séverine Vermeire; Paul Rutgeerts; Uwe Himmelreich; Jan L Ceuppens; Karel Geboes; Gert Van Assche
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.